Blinded Randomized trial of Anticoagulation to prevent Ischemic stroke and Neurocognitive impairment in AF (BRAIN-AF): Methods and design
ConclusionBRAIN-AF will determine whether oral anticoagulation therapy with rivaroxaban compared with standard of care reduces the risk of stroke, TIA or cognitive decline in patients with non-valvular AF and a low risk of stroke.
Source: Canadian Journal of Cardiology - Category: Cardiology Source Type: research
More News: Bleeding | Brain | Canada Health | Cardiology | Dementia | Heart | Ischemic Stroke | Neurology | Stroke | Study